Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Study of the Safety and Bioactivity of AXT107 Injected Suprachoroidally in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05859776 is registered in ClinicalTrials.gov with AsclepiX Therapeutics, Inc. as lead sponsor.

NCT NCT05859776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05859776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Study of the Safety and Bioactivity of AXT107 Injected Suprachoroidally in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Lead sponsor
AsclepiX Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 19, 2023
Completion date
May 31, 2025
Enrollment
15 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration